Chokri Ben Lamine: Strategic Decision Making in Hematology under Competing Risks
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Game theory in Hematology equals strategic decision-making under competing risks (disease vs toxicity vs cost vs time).
Core idea: optimize outcome when multiple players (tumor, host, physician, system) interact․
AML induction vs wait
- aggressive disease equals ‘move early’ (dominant strategy)
- frail pt equals delay/low-intensity leads to minimize loss (minimax)․
MRD-guided decisions
- MRD positive leads to escalate (allo-SCT)
- MRD negative leads to de-escalate
- dynamic strategy equals sequential game․
CAR-T vs bispecific vs SCT
- competing strategies with different payoffs (CR, toxicity, durability)
- choose based on patient fitness plus tumor biology leads to expected utility maximization․
GVHD vs GVL balance
- immunosuppression decrease GVHD but increase relapse
- optimal point equals Nash equilibrium between immune control and toxicity․
Anticoagulation in cancer thrombosis
- bleeding risk vs clot risk
- adjust dose/timing leads to risk-dominant strategy․
Transfusion thresholds (PBM)
- liberal vs restrictive
- restrictive often ‘dominant strategy’ leads to same outcomes, fewer risks․
Antibiotic use in FN
- overuse leads to resistance
- underuse leads to mortality
- stewardship equals repeated game with system-level payoff․
Clonal evolution (AML/CLL/MM)
- tumor adapts to therapy equals ‘evolutionary game’
- combination/sequencing prevents resistant clone dominance․
Resource allocation (ICU beds, CAR-T slots)
- prioritize pts with highest benefit probability
- utility plus fairness balance․
One-liner
Hematology decisions equals multi-step strategic games leads to best outcomes when timing, sequencing, and risk trade-offs are optimized.”
Stay updated with Hemostasis Today.
-
May 15, 2026, 04:34Aryabhatta Sadhu: Honoured to Speak at The 5th European Congress on Hematology and Blood Disorders
-
May 15, 2026, 04:28Ashkan Shoamanesh: Thrilled to Be Leading The Global INTERCEPT Trial
-
May 15, 2026, 04:00Danny Hsu: Join The THANZ Webinar on The Art and Science of Anticoagulation Stewardship
-
May 15, 2026, 03:48Deepak Yadav: What If the Way We Classify Stroke Tissue Is Too Simplistic for Modern Stroke Care?
-
May 15, 2026, 03:32Damon Race: Can Gene Therapy Deliver Durable Expression Over Time?
-
May 14, 2026, 17:17Abhijit D: Reticulocyte Count Methods in Hematology Laboratories
-
May 14, 2026, 16:46Michele Romoli: Neurointerventional Workforce Gaps and Stroke Thrombectomy Access in Europe
-
May 14, 2026, 16:37Reyes Calzada Bau: What It Means to Live with Immune Thrombocytopenia
-
May 14, 2026, 16:34Julia Owens: Improving Acute Stroke Care for Patients Without Timely Intervention